Tracer library / [68Ga]HTK03187

[68Ga]HTK03187

Also written as [Ga-68]Ga-HTK03187

Radionuclide: Ga-68 t½ 67.71 min
Modality: PET
Production route: —
Stage: Reported once
Syntheses indexed: 1

Prostate cancer

What it is

Compound class: PSMA-targeted radioligand (Lys-urea-Cms pharmacophore, DOTA-conjugated)
Target / mechanism: Binds prostate-specific membrane antigen (PSMA) PMID 37649602
Clinical application: PSMA-targeted imaging/radioligand therapy in prostate cancer (LNCaP tumor model) PMID 37649602
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	HPLC+SPE	68-75% decay-corrected	>99%	HTK03187 (DOTA-conjugated precursor)	37649602 2023 Theranostics Purified [68Ga]GaCl3 in 0.5 mL water was added into a 4‐mL glass vial preloaded with 0.7 mL of HEPES buffer (2 M, pH 5.0) and 50 μg precursor. The radiolabeling reaction was carried out under microwave heating for 1 min. - the desired 68Ga-labeled HTK03177 and HTK03187 were obtained in 68-75% decay-corrected radiochemical yield

Need this precursor?We can point you to suppliers for [68Ga]HTK03187, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37649602. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37649602: 'HTK03187 (DOTA-conjugated precursor)'. | Stage 30 (2026-09-18): Modality was 'Therapy' -- a bucket value given to every agent found by the therapy-oriented bulk search (stages 21-22), not a source statement. Corrected to PET: Ga-68 is a positron emitter used only for PET imaging. Linked articles: PMID 37649602.